4-((1-Methyl-1H-pyrazol-4-yl)oxy)aniline | 1600142-61-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-((1-Methyl-1H-pyrazol-4-yl)oxy)aniline
• 英文别名: 4-(1-methylpyrazol-4-yl)oxyaniline
• CAS: 1600142-61-7
• 化学式: C₁₀H₁₁N₃O
• 分子量: 189.21
• InChiKey: DCCRIZZKBMDQEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted bicyclic derivatives for the treatment of abnormal cell growth
  申请人：——

  公开号：US20020169165A1

  公开（公告）日：2002-11-14

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 5 , R 11 , m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  该发明涉及公式11的化合物，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R5、R11、m和p如本文所定义。该发明还涉及通过给予公式1的化合物治疗哺乳动物的异常细胞增长的方法，并且涉及用含有公式1的化合物的制药组合物治疗这种疾病的方法。该发明还涉及制备公式1的化合物的方法。
• SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Pfizer Products Inc.

  公开号：EP1292591A2

  公开（公告）日：2003-03-19
• US6890924B2
  申请人：——

  公开号：US6890924B2

  公开（公告）日：2005-05-10
• US7332493B2
  申请人：——

  公开号：US7332493B2

  公开（公告）日：2008-02-19
• [EN] SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH<br/>[FR] DERIVES BICYCLIQUES SUBSTITUES DESTINES AU TRAITEMENT DE LA CROISSANCE CELLULAIRE ANORMALE
  申请人：PFIZER PROD INC

  公开号：WO2001098277A2

  公开（公告）日：2001-12-27

  The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R?1, R3, R4, R5, R11¿, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders which contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).